Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TGTX 
TG Therapeutics Inc (TGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TGTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $43.57
1 Year Target Price $43.57
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.84% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.56B USD | Price to earnings Ratio 92.24 | 1Y Target Price 43.57 |
Price to earnings Ratio 92.24 | 1Y Target Price 43.57 | ||
Volume (30-day avg) 7 | Beta 1.97 | 52 Weeks Range 22.61 - 46.48 | Updated Date 10/15/2025 |
52 Weeks Range 22.61 - 46.48 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.32% | Operating Margin (TTM) 24.69% |
Management Effectiveness
Return on Assets (TTM) 9.72% | Return on Equity (TTM) 26.63% |
Valuation
Trailing PE 92.24 | Forward PE 42.92 | Enterprise Value 5818527372 | Price to Sales(TTM) 12.25 |
Enterprise Value 5818527372 | Price to Sales(TTM) 12.25 | ||
Enterprise Value to Revenue 12.81 | Enterprise Value to EBITDA 59.62 | Shares Outstanding 158665613 | Shares Floating 135160522 |
Shares Outstanding 158665613 | Shares Floating 135160522 | ||
Percent Insiders 9.73 | Percent Institutions 64.56 |
Upturn AI SWOT
TG Therapeutics Inc
Company Overview
History and Background
TG Therapeutics, Inc. was founded in 2011. It is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Core Business Areas
- Oncology: Focused on developing and commercializing therapies for B-cell malignancies.
Leadership and Structure
Michael S. Weiss is the Chairman and Chief Executive Officer. The company has a typical corporate structure with departments for research & development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Ublituximab: A novel glycoengineered anti-CD20 monoclonal antibody. Ublituximab (branded as Briumvi) is approved for relapsing forms of multiple sclerosis (RMS). Competitors include Ocrevus (Roche), Kesimpta (Novartis), and Mavenclad (Merck).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. It is highly competitive with a few large players and numerous smaller biotech companies.
Positioning
TG Therapeutics is a smaller biotech company focusing on niche markets within oncology and autoimmune diseases. Its competitive advantage lies in its focus on specific targets and its novel glycoengineering technology.
Total Addressable Market (TAM)
The TAM for relapsing forms of multiple sclerosis (RMS) is estimated to be in the billions of dollars annually. TG Therapeutics is positioned to capture a portion of this TAM with Briumvi.
Upturn SWOT Analysis
Strengths
- FDA approval of Briumvi for RMS
- Novel glycoengineering technology
- Experienced management team
- Focus on niche markets
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on a small number of products
- Commercialization risks
- Historical challenges with regulatory approval for other indications
Opportunities
- Expanding indications for ublituximab
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies or assets
- Growth in the autoimmune disease market
Threats
- Competition from established players
- Regulatory hurdles
- Patent challenges
- Pricing pressures
Competitors and Market Share
Key Competitors
- RHHBY
- NVS
- MRK
Competitive Landscape
TG Therapeutics faces intense competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its novel glycoengineering technology and focus on specific targets.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the development and potential commercialization of new therapies.
Future Projections: Future growth is dependent on the successful commercialization of Briumvi and the development of new products. Analyst estimates vary widely.
Recent Initiatives: Focus on the launch and expansion of Briumvi in the RMS market.
Summary
TG Therapeutics is a growing biopharmaceutical company with a focus on B-cell malignancies and autoimmune diseases. The approval of Briumvi for RMS is a significant milestone, but the company faces strong competition and commercialization risks. Successful execution of its commercial strategy and development of new products will be crucial for future growth. The company has a small marketshare compared to it's competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TG Therapeutics Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 1995-12-14 | Chairman, CEO & President Mr. Michael S. Weiss Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 370 | Website https://www.tgtherapeutics.com |
Full time employees 370 | Website https://www.tgtherapeutics.com | ||
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.